Related Experiment Video
Updated: Jun 17, 2026
10:26
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
Dabigatran etexilate in venous thromboembolism
1Medical Information Department, Thomson Reuters, Barcelona, Spain. scientific.prousjournals@thomsonreuters.com
Drugs of Today (Barcelona, Spain : 1998)
|January 14, 2010
Summary
Dabigatran etexilate (Pradaxa) offers effective prevention of venous thromboembolism (VTE) after hip or knee surgery. This direct thrombin inhibitor shows comparable safety and efficacy to enoxaparin, presenting a convenient oral alternative.
Area of Science:
- Pharmacology
- Thrombosis Research
- Clinical Trials
Background:
- Dabigatran etexilate is an oral prodrug of dabigatran, a direct thrombin inhibitor (DTI).
- DTIs represent a novel class of anticoagulants.
- Understanding its pharmacokinetic and pharmacodynamic properties is crucial for clinical application.
Purpose of the Study:
- To evaluate the efficacy and safety of dabigatran etexilate for VTE prevention.
- To compare dabigatran etexilate with enoxaparin in patients undergoing major orthopedic surgery.
- To assess the pharmacokinetic profile and drug interactions of dabigatran etexilate.
Main Methods:
- Two large, randomized, double-blind clinical trials were conducted.
- Patients undergoing total hip or knee replacement surgery received either dabigatran etexilate or enoxaparin.
- Pharmacokinetic parameters, including peak plasma concentrations and linearity, were analyzed.
Main Results:
- Dabigatran etexilate demonstrated non-inferiority to enoxaparin in preventing VTE.
- Pharmacokinetics were linear across a wide dose range with rapid absorption.
- Safety profiles were similar, with comparable rates of major bleeding and adverse events.
Conclusions:
- Dabigatran etexilate is a safe and effective oral alternative for VTE prophylaxis.
- Its predictable anticoagulation and convenient dosing offer advantages over traditional therapies.
- The drug exhibits favorable pharmacokinetic properties and minimal drug interactions.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...